A manufacturer intends to market an herbal supplement composed of widely available ingredients. Which regulatory pathway applies?

• A. NDA
• B. DESI
• C. OTC Monograph
• D. ANDA

Answer: (C)

The main idea here is how an herbal product can be brought to market without a full drug approval when its ingredients are well known and widely available. If the product is intended for over-the-counter sale and its ingredients, dosing, and labeling fit an established OTC monograph, it can be marketed under that monograph rather than going through a new drug application. This route lets manufacturers stay within predefined safety, efficacy, and labeling parameters already set for those ingredients, without the separate premarket NDA process.

Think of it this way: an OTC monograph provides a framework for nonprescription products that use specific ingredients in specified amounts, with approved labeling. The other pathways don’t fit this scenario. A new drug approval (NDA) is for introducing a completely new active substance or new indications requiring extensive safety and efficacy data. DESI was a historical program used to evaluate older drugs’ efficacy and isn’t a current marketing pathway. ANDA is for generic versions of drugs that already have an approved reference product, not for fresh herbal supplements.